多西他赛二线治疗非小细胞肺癌每周方案的临床分析

Clinical study of weekly Docetaxel as second line therapy to non-small cell lung cancer

目的研究和评价单药多西他赛二线治疗非小细胞肺癌每周方案的临床疗效和不良反应。方法对2005年11月-2007年3月同济大学附属肺科医院收治的60例一线治疗失败的非小细胞肺癌患者，应用单药多西他赛第1天和第8天用药，剂量为35mg／（m^2·次）化疗，21d为1个周期，每个周期评价毒性反应，至少化疗2个周期后评价疗效。结果60例患者共经历203个周期多西他赛化疗，年龄39～78岁，60例患者完全缓解（complete response，CR）O例，部分缓解（partial response，PR）7例（11．7％），稳定（stable disease，SD）19例（31．6％），疾病控制率（disease control rate，DCR）43．3％，无疾病进展生存时间（progression free survival，PFS）14周。结论单药多西他赛每周方案二线治疗非小细胞肺癌患者疗效较好，可延缓患者病情进展，不良反应相对较轻，适合在一般状况较差有合并疾病的患者二线治疗中应用。

Objective To evaluate the clinical efficacy and side effect of weekly Docetaxel as second line therapy on non-small-cell lung cancer. Methods Data of sixty cases with non-small-cell lung cancer whose first line therapy had failed were collected retrospectively from Oct 2005 to Mar 2007. All the cases received second-line setting of weekly Docetaxel 35 mg/m^2 at 1st and 8th days. Twenty-one days as a cycle. Side effects and curative effects were evaluated after 1 or 2 cycles respectively. Results Sixty patients aged from 39 to 78 years received 203 cycles of treatment of Docetaxel. No patient got a complete response, 7 cases （11. 7% ）got a partial response, 19 （31. 6% ） got a stable and the disease control rate was 43.3%. The median progression free survival was 14 weeks. Conclusion Weekly Docetaxel as second line therapy is effective in non-small cell patients, and can delay the disease progression with less side effects. It should be recommended to the non-small-cell lung cancer patients with poor performance status or complications.